Tirzepatide
6 articles in this topic.
All Articles
What Is Tirzepatide? The Dual GIP/GLP-1 Agonist
Tirzepatide activates both GIP and GLP-1 receptors, producing up to 22.5% weight loss in SURMOUNT-1. Here's how the dual mechanism works and what sets it apart.
SURMOUNT Trials: Tirzepatide Weight Loss Data
All five SURMOUNT trials explained: 22.5% weight loss in SURMOUNT-1, diabetes prevention at 3 years, and the head-to-head win over semaglutide.
Tirzepatide Dose Response: Weight Loss at Each Dose
Tirzepatide produces 16%, 21.4%, and 22.5% weight loss at 5 mg, 10 mg, and 15 mg. Here's the dose-response data from every major SURMOUNT trial.
Tirzepatide's Dual Mechanism vs Single GLP-1 Agonists
Tirzepatide activates both GIP and GLP-1 receptors, producing greater weight loss and glycemic control than GLP-1-only drugs. How the dual mechanism works.
Mounjaro vs Zepbound: Same Drug, Different Labels
Mounjaro and Zepbound are both tirzepatide. One is approved for type 2 diabetes, the other for obesity. Here is what differs and what does not.